Open Access

Incorporating Lp(a) into risk classification for patients with ASCVD.

Topic: Cardiovascular Risk Assessment
Sponsored by Novartis Pharma AG

Congress Presentation

About the speaker

Professor Ingo Hilgendorf

University of Freiburg, Freiburg (Germany)
2 presentations
1 follower

4 more presentations in this session

Welcome and introduction.

Speaker: Professor J. Zamorano Gomez (Madrid, ES)


Uncovering the risks: the value of early assessment in ASCVD - A clinical case.

Speaker: Professor J. Zamorano Gomez (Madrid, ES)


Guidance on Lp(a) measurement: why, how, when?

Speaker: Doctor P. Kamstrup (Herlev, DK)


Access the full session

Uncovering the hidden risk: why lipoprotein(a) testing is crucial

Speakers: Professor I. Hilgendorf, Professor J. Zamorano Gomez, Professor J. Zamorano Gomez, Doctor P. Kamstrup

About the event


ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb